Cost-of-illness model for venous thromboembolism

      We read with interest the well-written review article of venous thromboembolism (VTE) costs «The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs» by Grosse and colleagues [
      • Grosse S.D.
      • Nelson R.E.
      • Nyarko K.A.
      • Richardson L.C.
      • Raskob G.E.
      The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs.
      ]. VTE continues to be a major public health issue worldwide: suboptimal preventative strategies in many areas and models to better evaluate its global economic impact are lacking and currently far from being optimal in their estimates of VTE and VTE-associated rates and costs [
      • ISTH Steering Committee for World Thrombosis Day
      Thrombosis: a major contributor to global disease burden.
      ].
      Fig. 1
      Fig. 1Comparison of healthcare and general Consumer Price Index in the US from 1966 to 2015 (data retrieved from the US Bureau of Labor Statistics; http://www.bls.gov).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grosse S.D.
        • Nelson R.E.
        • Nyarko K.A.
        • Richardson L.C.
        • Raskob G.E.
        The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs.
        Thromb. Res. 2016; 137: 3-10
        • ISTH Steering Committee for World Thrombosis Day
        Thrombosis: a major contributor to global disease burden.
        Thromb. Haemost. 2014; 112: 843-852
        • Mahan C.E.
        • Borrego M.E.
        • Woersching A.L.
        • et al.
        Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
        Thromb. Haemost. 2012; 108: 291-302
        • Mahan C.E.
        • Holdsworth M.T.
        • Welch S.M.
        • Borrego M.
        • Spyropoulos A.C.
        Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event.
        Thromb. Haemost. 2011; 106: 405-415
        • Konstantinides S.V.
        • Barco S.
        • Lankeit M.
        • Meyer G.
        Management of pulmonary embolism: an update.
        J. Am. Coll. Cardiol. 2016; 67: 976-990
        • Barco S.
        • Woersching A.L.
        • Spyropoulos A.C.
        • Piovella F.
        • Mahan C.E.
        European Union-28: an annualised cost-of-illness model for venous thromboembolism.
        Thromb. Haemost. 2016; 115: 800-808
        • Deitelzweig S.B.
        • Johnson B.H.
        • Lin J.
        • Schulman K.L.
        Prevalence of clinical venous thromboembolism in the USA: current trends and future projections.
        Am. J. Hematol. 2011; 86: 217-220
        • Grosse S.D.
        Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al.
        Thromb. Haemost. 2012; 107 (author reply 4-5): 192-193
        • Mossialos E.
        • Wenzl M
        • Osborn R.
        • Sarnak D.
        International Profiles of Health Care Systems.
        The Commonwealth Fund. 2015: 2016
        • Chen W.Y.
        • Liang Y.W.
        • Lin Y.H.
        Is the United States in the middle of a healthcare bubble?.
        Eur. J. Health Econ. 2016; 17: 99-111
        • Emanuel E.J.
        How Obamacare is changing the startup world.
        Fortune. 2016;
        • Squires D.
        Explaining High Health Care Spending in the United States: An International Comparison of Supply, Utilization, Prices, and Quality.
        May 3, 2012 (ed)
        • Becattini C.
        • Agnelli G.
        • Salvi A.
        • et al.
        Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism.
        Thromb. Res. 2010; 125 (e82-e6)
        • Barco S.
        • Heuschen C.B.
        • Salman B.
        • et al.
        Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals.
        J. Thromb. Haemost. 2016; 14: 1364-1373
        • Cohen A.T.
        • Agnelli G.
        • Anderson F.A.
        • et al.
        Venous thromboembolism (VTE) in Europe – the number of VTE events and associated morbidity and mortality.
        Thromb. Haemost. 2007; 98: 756-764